Skip to main content
Equibles
RANI logo

RANI · Rani Therapeutics Holdings, Inc. · Metrics

Track RANI — free

Use RANI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RANI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.58 +0.02 (+4.03%) Play latest call Q4 2025 earnings call transcript
Rebalance outlook locked
Market Cap
$80.74M
Shares
139.40M
Volume · Nov 4 169.69K Avg daily vol (3M) 593.77K

RANI metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.56
Market cap
$80.74M

Price action

20 metrics
Price change (1W)
-10.6%
Price change (30D)
-28.8%
Price change (3M)
-31.1%
Price change (6M)
-40.8%
Price change (YTD)
-59.1%
Price change (1Y)
-74.9%
Trailing year
Price change (5Y)
-97.9%
52-week high
$2.50
52-week low
$0.55
Change from 52-week high
-77.9%
Change from 52-week low
+0.0%
Annualized volatility
85.6%
Annualized volatility (3M)
62.8%
Beta
2.2
RSI (14D)
27.4
Price vs SMA 50
-27.6%
Price vs SMA 200
-40.6%
Avg volume (3M)
593,247
Relative volume
0.7
Average dollar volume
$462,830

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
139.40M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
15.6×
reciprocal yield 6.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
16.6×
reciprocal yield 6.0%
P / book
2.1
reciprocal yield 48.4%
FCF yield
-25.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-30.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
72.2×
reciprocal yield 1.4%
EV / revenue historical average (5Y)
82.5×
reciprocal yield 1.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-26

Profitability

9 metrics
Gross margin
—
Operating margin
-675.8%
Trailing 12 months
Net margin
-505.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$32.96M
Net income (TTM)
−$24.67M
Trailing 12 months
Diluted EPS (TTM)
$-0.13
FCF margin
-417.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+58.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.88M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+412.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
+28.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-62.9%
Return on assets
-40.5%
Debt / equity
0.0
Current ratio
5.3
EBITDA (TTM)
−$32.24M
Free cash flow (TTM)
−$20.34M
Quick ratio
5.3
Interest coverage
-28.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.87M
Latest balance sheet
Cash & equivalents
$4.87M
Total assets
$60.84M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$20.29M
Capital expenditures (TTM)
$47,000
R&D (TTM)
$18.31M
SG&A (TTM)
—
Stock compensation (TTM)
$9.09M
R&D / revenue
375.4%
Stock compensation / revenue
186.4%

Ownership (13F)

9 metrics
13F filers
68
13F filer change QoQ
-8
Institutional ownership
32.8%
Conviction holders (share of 13F filers)
1.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+21.5%
Holder tenure
3.7
Price vs estimated holder cost
-57.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.8%

Short interest

3 metrics
Short interest
5.9%
Latest settlement · 14.2 days to cover
Days to cover
14.2d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1856725 CUSIP 753018100 13F (30d) 12 filings 12 filers Visit website Investor relations